Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

Summary

A Phase 1 open-label, non-randomized dose escalation study to determine the maximum tolerated dose (MTD) and characterize the safety and tolerability of Birinapant (TL32711).

Timeline

Start

2009-11

Primary completion

2012-08

Completion

2013-03

Drugs

Indications